Macter International Limited
Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.
Public pharmaceutical manufacturer · Karachi · Pakistan
Publicly listed Pakistan pharmaceutical manufacturer with branded-generic, biotech and contract-manufacturing operations.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Company type
- Public pharmaceutical manufacturer
- Address
- F-216, S.I.T.E., Karachi-75700, Pakistan · 75700
- Website
- macter.com ↗
- Phone
- +92 21 32575311-14
- Official company profile ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 88%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Empozin-M | Empagliflozin + Metformin | 12.5 mg + 500 mg | Tablet | 28's | 093095 | PKR 1,647.51 | PKR 58.84/tablet | 15% above median |
| Empozin-M | Empagliflozin + Metformin | 12.5 mg + 500 mg | Tablet | 14's | 093095 | PKR 841.01 | PKR 60.07/tablet | 18% above median |
| Empozin-M | Empagliflozin + Metformin | 5 mg + 1000 mg | Tablet | 28's | 093096 | PKR 1,416.83 | PKR 50.60/tablet | Near median |
| Empozin-M | Empagliflozin + Metformin | 5 mg + 1000 mg | Tablet | 14's | 093096 | PKR 722.94 | PKR 51.64/tablet | Near median |
| Empozin-M | Empagliflozin + Metformin | 12.5 mg + 1000 mg | Tablet | 28's | 093097 | PKR 1,676.58 | PKR 59.88/tablet | Near median |
| Empozin-M | Empagliflozin + Metformin | 12.5 mg + 1000 mg | Tablet | 14's | 093097 | PKR 855.55 | PKR 61.11/tablet | Near median |
| Epilepsin | Carbamazepine | 200 mg | Tablet | 50 | 011654 | PKR 540.84 | PKR 10.82/tablet | Near median |
| Epilepsin | Carbamazepine | 100 mg/5 mL | Suspension | 100ml | 019342 | PKR 211.94 | PKR 2.12/mL | 20% above median |
| Epocan | Epoetin alfa | 2,000 IU | Injection | 1's | 092610 | PKR 2,103.50 | PKR 2,103.50/vial/unit | No comparator |
| Epocan | Epoetin alfa | 2000 IU | Injection | 1's | 092610 | PKR 2,103.50 | PKR 2,103.50/vial/unit | No comparator |
| Epocan | Epoetin alfa | 4000 IU | Injection | 1's | 092611 | PKR 3,883.01 | PKR 3,883.01/vial/unit | No comparator |
| Epocan | Epoetin alfa | 10,000 IU | Injection | 1's | 092612 | PKR 8,736.74 | PKR 8,736.74/vial/unit | 5% above median |
| Epocan | Epoetin alfa | 10000 IU | Injection | 1's | 092612 | PKR 8,736.74 | PKR 8,736.74/vial/unit | 5% above median |
| Femrosa | Iron protein succinylate | 800 mg | Syrup | 60ml | 039517 | PKR 194.61 | PKR 3.24/mL | 9% above median |
| Haematrix | Tranexamic acid | 50 mg | Injection | 5 | 021723 | PKR 281.53 | — | No comparator |
| Hart | Carvedilol | 25 mg | Tablet | 10 | 037195 | PKR 493.18 | PKR 49.32/tablet | 48% above median |
| Hart | Carvedilol | 3.125 mg | Tablet | 10 | 044033 | PKR 197.27 | PKR 19.73/tablet | 30% above median |
| Hart | Carvedilol | 6.25 mg | Tablet | 30 | 044034 | PKR 394.55 | PKR 13.15/tablet | 30% above median |
| Hart | Carvedilol | 12.5 mg | Tablet | 10 | 044035 | PKR 147.96 | PKR 14.80/tablet | 16% above median |
| Heberbiovac | Hepatitis B vaccine (recombinant HBsAg) | 20 mcg/1 mL | Vaccine injection | 1's | 020647 | PKR 750.95 | PKR 750.95/vial/unit | No comparator |
| Heberbiovac | Hepatitis B vaccine (recombinant HBsAg) | 10 mcg | Vaccine injection | 1's | 020648 | PKR 450.85 | PKR 450.85/vial/unit | 6% below median |
| Heberpenta | Diphtheria + Tetanus + Whole-cell Pertussis + Hepatitis B + Hib conjugate vaccine (DTwP-HepB-Hib) | D 25 LF + T 10 LF + wP 16 OU + HBsAg 10 mcg + Hib PRP-T 10 mcg/dose | IM vaccine injection | 1's | 066063 | PKR 4,956.74 | PKR 4,956.74/vial/unit | No comparator |
| Hebervital G-CSF | Filgrastim | 0.3 mg | Injection | 1's | 053836 | PKR 6,815.50 | PKR 6,815.50/vial/unit | No comparator |
| Hepanox | Enoxaparin | 40 mg/0.4 mL | Injection | 2's vial | 115181 | PKR 1,711.70 | PKR 855.85/vial/unit | No comparator |
| Hepanox | Enoxaparin | 60 mg/0.6 mL | Injection | 2's vial | 115182 | PKR 2,506.16 | PKR 1,253.08/vial/unit | No comparator |
| Infazith | Azithromycin | 500 mg | Tablet | 6's | 105444 | PKR 548.53 | PKR 91.42/tablet | 8% above median |
| Infazith | Azithromycin | 250 mg | Tablet | 6's | 105445 | PKR 299.20 | PKR 49.87/tablet | 6% above median |
| Infazith Susp | Azithromycin | 200 mg/5 mL | Suspension | 15ml | 105446 | PKR 335.97 | PKR 22.40/mL | Near median |
| Inhixa | Heparin sodium | 5000 IU | Injection | 10's | 115185 | PKR 14,942.47 | PKR 1,494.25/vial/unit | Near median |
| Inhixa | Heparin sodium | 5000 IU | Injection | 1's X 5ml | 115185 | PKR 1,556.51 | PKR 311.30/mL | 16% above median |
| Inhixa | Heparin sodium | 5000 IU | Injection | 5's | 115185 | PKR 7,471.00 | PKR 1,494.20/vial/unit | Near median |
| Inspirol | Salbutamol | 200 mcg | Inhalation capsule | 30's | 091147 | PKR 75.32 | PKR 2.51/capsule | 46% below median |
| Inspirol HFA Inhaler | Salbutamol | 100 mcg | Metered-dose inhaler | 200 meter dose | 045160 | PKR 413.07 | — | No comparator |
| Ketcyn | Ketamine | 50 mg/mL | Injection | 1 x 2 ml | 021724 | PKR 82.61 | PKR 41.31/mL | 77% above median |
| Ketcyn | Ketamine | 50 mg/mL | Injection | 1 x 10 ml | 021724 | PKR 243.73 | PKR 24.37/mL | Near median |
| Ketcyn | Ketamine | 50 mg | Injection | 1 x 10 ml | 021724 | PKR 243.73 | PKR 24.37/mL | 7% above median |
| Ketcyn | Ketamine | 50 mg | Injection | 1 x 2 ml | 021724 | PKR 82.61 | PKR 41.31/mL | 81% above median |
| Ketcyn | Ketamine | 50 mg/mL | Injection | 5 x 5 ml | 021725 | PKR 805.47 | PKR 32.22/mL | 38% above median |
| Ketcyn | Ketamine | 50 mg/mL | Injection | 1 x 5 ml | 021725 | PKR 171.42 | PKR 34.28/mL | 47% above median |
| Ketcyn | Ketamine | 50 mg | Injection | 1 x 5 ml | 021725 | PKR 171.42 | PKR 34.28/mL | 50% above median |
| Letrobol | Letrozole | 2.5 mg | Tablet | 30's | 108609 | PKR 14,383.60 | PKR 479.45/tablet | 19% above median |
| Letrobol | Letrozole | 2.5 mg | Tablet | 10's | 108609 | PKR 23,972.66 | PKR 2,397.27/tablet | 497% above median |
| Lignomax AD | Lidocaine + Adrenaline | 20 mg/mL + 0.005 mg/mL | Injection | 50 x 10 ml | 021728 | PKR 1,459.52 | PKR 2.92/mL | Near median |
| Lignomax AD | Lidocaine + Adrenaline | 20 mg/mL + 0.005 mg/mL | Injection | 10 x 10 ml | 021728 | PKR 298.39 | PKR 2.98/mL | Near median |
| Linowin | Linezolid | 600 mg | Tablet | 12's | 057793 | PKR 5,351.95 | PKR 446.00/tablet | 13% above median |
| Linowin | Linezolid | 100 mg/5 mL | Dry suspension | 60ml | 057794 | PKR 732.86 | PKR 12.21/mL | 13% above median |
| Linowin | Linezolid | 400 mg/200 mL | Solution for infusion | 1 | 067209 | PKR 864.89 | — | No comparator |
| Linowin | Linezolid | 400 mg | IV infusion | 1 | 067209 | PKR 864.89 | — | No comparator |
| Linowin | Linezolid | 600 mg | IV infusion | 1's | 067210 | PKR 1,297.34 | PKR 1,297.34/vial/unit | 10% above median |
| Linowin | Linezolid | 200 mg/100 mL | Solution for infusion | 1 | 067211 | PKR 748.13 | — | No comparator |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.